Depressive symptoms and functional decline following coronary interventions in older patients with coronary artery disease: a prospective cohort study

M. Elizabeth Wilcox¹,², Elizabeth A. Freiheit³, Peter Faris⁴,⁵, David B. Hogan⁴,⁶, Scott B. Patten⁴,⁷, Todd Anderson⁸,⁹,¹⁰, William A. Ghali⁴,⁸,¹⁰, Merril Knudtson⁸,⁹,¹⁰, Andrew Demchuk¹¹ and Colleen J. Maxwell¹²,¹³,⁴*

Abstract

**Background:** Depressive symptoms are prevalent in patients with coronary artery disease (CAD). It is unclear, however, how depressive symptoms change over time and the impact of these changes on long-term functional outcomes. We examined the association between different trajectories of depressive symptoms over 1 year and change in functional status over 30 months among patients undergoing coronary angiography.

**Methods:** This was a prospective cohort study of 350 patients aged 60 and older undergoing non-emergent cardiac catheterization (October 2003–February 2007). A dynamic measure of significant depressive symptoms (i.e., Geriatric Depression Scale score 5+) capturing change over 12 months was derived that categorized patients into the following groups: (i) no clinically important depressive symptoms (at baseline, 6 and 12 months); (ii) baseline-only symptoms (at baseline but not at 6 and 12 months); (iii) new onset symptoms (not at baseline but present at either 6 or 12 months); and, (iv) persistent symptoms (at baseline and at either 6 or 12 month assessment). Primary outcomes were mean change in Older Americans Resources and Services (OARS) instrumental (IADL) and basic activities of daily living (BADL) scores (range 0–14 for each) across baseline (pre-procedure) and 6, 12, and 30 months post-procedure visits.

**Results:** Estimates for the symptom categories were 71 % (none), 9 % (baseline only), 8 % (new onset) and 12 % (persistent). In adjusted models, patients with persistent symptoms showed a significant decrease in mean IADL and BADL scores from baseline to 6 months (−1.32 [95 % CI −1.78 to −0.86] and −0.63 [−0.97 to −0.30], respectively) and from 12 to 30 months (−0.79 [−1.27 to −0.31] and −1.00 [−1.35 to −0.65], respectively). New onset symptoms were associated with a significant decrease in mean IADL scores at 6 months and from 6 to 12 months. Patients with no depressive symptoms showed little change in scores whereas those with baseline only symptoms showed significant improvement in mean IADL at 6 months.

**Conclusions:** Patients with persistent depressive symptoms were at greatest risk for worse functional status 30 months following coronary interventions. Proactive screening and follow-up for depression in this population offers prognostic value and may facilitate the implementation of targeted interventions.

**Keywords:** Depression, Coronary artery disease, Coronary intervention, Functional outcomes, Functional decline, Cohort study

*Correspondence: colleen.maxwell@uwaterloo.ca

© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
**Background**

In older hospitalized adults, depressive symptoms are common and associated with a variety of adverse outcomes including worse quality of life [1, 2], reduced physical function [3], caregiver burnout [4], and increased mortality [5, 6]. Among older patients with coronary artery disease (CAD), estimates for minor and major depressive symptoms range from 30 to 45% [7–9]. This compares to a prevalence of about 15% among community-based samples of adults aged 60 years or older [10]. In CAD patients, depressive symptoms represent an independent risk factor for all-cause mortality and adverse cardiovascular events [7, 11, 12]. Although baseline measures of depression have been linked to poorer functional outcomes in older adults with CAD [13–15], most of this research has failed to consider the dynamic nature of depressive symptoms in this population or the associated consequences for longer-term health and functional outcomes. This is a significant knowledge gap as symptoms of depression may be transient, episodic or persistent [16]. With increasing survival rates among older adults with CAD undergoing coronary interventions [17], it is important to consider how the course of depressive symptoms may impact long-term functional independence in this vulnerable population.

In one of the few studies to explore this area, Sin and colleagues demonstrated a significant association between increases in depressive symptoms over 5 years and decreases in basic (but not instrumental) activities of daily living among 658 older adults with stable coronary heart disease [18]. In this study, changes in select disease severity markers (including frequency of angina and ejection fraction) were not found to be predictive of change in functional status. As this study was limited to older patients with stable disease and by an assessment of depression at baseline and at the 5-year follow-up only, further work to explore the trajectory and functional consequences of depressive symptoms in older patients undergoing coronary interventions is needed.

Emerging evidence suggests not all depressed patients with CAD are at risk of adverse health outcomes. Patients with new onset or persistent symptoms appear to be at highest risk for mortality and cardiac events [19–21]. Among older community-dwelling adults, those exhibiting persistent depressive symptoms show an increased risk for cognitive and functional decline [22–24]. In a previous study of CAD patients undergoing coronary interventions, we observed that participants with persistent depressive symptoms had significantly greater declines at 30 months in attention/executive function, learning/memory, verbal fluency and global cognition [25]. Although others have examined predictors and outcomes of trajectories in depressive symptoms among patients with cardiovascular disease [2, 18], the impact of different trajectories in depressive symptoms assessed among CAD patients pre- and post-coronary interventions on functional change over a longer-term (beyond 1 year) remains to be explored. As we previously noted, while patients undergoing coronary interventions would be expected to exhibit significant variation in their symptoms, health status and well-being over time [25, 26], the impact of such variation on functional outcomes remains unknown.

Our aim was to examine the impact of change in clinically significant depressive symptoms over 1 year on long-term (30 month) change in instrumental (IADL) and basic activities of daily living (BADL) among older patients undergoing coronary catheterization who subsequently received coronary artery bypass graft (CABG) surgery, percutaneous coronary intervention (PCI) or medical therapy (MT).

**Methods**

**Study Design**

The Calgary Cardiac and Cognition (3C) Study was a prospective cohort investigation of the impact of neurocognitive and psychological factors on quality of life and functional status among older CAD patients undergoing evaluation for coronary revascularization.

Between October 2003 and May 2007 a total of 374 subjects aged 60 years and older were enrolled at a tertiary care hospital providing centralized cardiac services for residents of southern Alberta, Canada. Patients underwent coronary angiography (between October 2003 and February 2007) and post-catheterization, 128 underwent CABG surgery, 150 had PCI and 96 received MT. Trained cardiovascular research nurses screened all patients presenting for angiography for eligibility. Exclusion criteria included age < 60 years, emergency catheterization, prior revascularization and inability to provide informed written consent or complete the assessment due to language difficulties or severe cognitive and/or physical impairments. We purposefully oversampled those scheduled to undergo CABG and PCI (a comparison of our study sample to all eligible patients undergoing coronary catheterization during our recruitment period is available elsewhere) [25]. Ethics approval was obtained from the Conjoint Health Research Ethics Board, University of Calgary and informed consent was obtained from all participants.

A comprehensive standardized assessment including neuropsychological and physical performance tests, sociodemographic items, health behavior, self-rated health, activities of daily living and health-related quality of life measures was administered at baseline (pre-procedure), 6, 12, and 30 months post-procedure by trained research nurses or associates. Most (58%) baseline assessments were conducted in hospital with the remainder as well as all follow-up assessments in the participant’s home. A
trained psychometrician (blinded to patients’ clinical characteristics) reviewed and scored all cognitive testing. A structured interview with the patient’s identified informant (including Section H of the Cambridge Mental Disorders of the Elderly Examination-Revised [CAMDEX-R]) [27] was administered at all follow-up assessments, where possible. The study database was linked with the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) [28], a comprehensive registry of all patients undergoing cardiac catheterization in the province, for baseline clinical characteristics and data on repeat revascularization(s) and mortality during follow-up. Three patients could not be linked because of out-of-province catheterizations (n = 2) or missing hospital records (n = 1). Specific details on the 3C assessment battery, variable coding and data collection procedures have been published elsewhere [25].

During the 30 months, 40 participants moved or withdrew, 16 died and 7 subjects missed either the 6 or 12 month assessment but remained in the study (Fig. 1). Loss to follow-up at 30 months was 11% (40/374) of all enrolled subjects. The number of participants with outcome data at 6 and/or 12 months and included in our analyses was 350/374 (94%).

**Measurement of Depressive Symptoms**
The 15-item Geriatric Depression Scale (GDS) [29, 30] with a cut-point of ≥ 5 was used to define clinically important depressive symptoms. The GDS is a commonly used screening test for depression in older adults with established validity and reliability [31–33]. It is well suited for medically ill older patients because of its focus on non-somatic symptoms. As done in previous studies [22, 25], we created a dynamic measure of significant depressive symptoms with the following categories: (i) no clinically important depressive symptoms (at baseline, 6 and 12 months); (ii) baseline-only symptoms (at baseline but not at 6 and 12 months); (iii) new onset symptoms (not at baseline but present at either 6 or 12 months); and, (iv) persistent symptoms (at baseline and at either the 6 or 12 month assessment).

**Functional Outcomes**
Instrumental (IADL) and basic (BADL) activities of daily living were assessed with the Older Americans Resources and Services (OARS) Multidimensional Functional Assessment Questionnaire [34]. The IADL and BADL items demonstrate good reliability and validity and have been extensively utilized in past research on older adults [31]. The seven IADL items assess the respondent’s ability to use the telephone, travel distances independently, go shopping, prepare meals, do housework, take medicines and handle finances. The seven BADL items assess the respondent’s ability to feed self, dress/undress, groom self, walk, transfer to/from bed, bathe, and to use the bathroom. Response options were coded as 2 (can perform independently); 1 (requires some help/assistive device); or, 0 (is unable to perform on his/her own). Total scores for both scales ranged from 0 to 14, with lower scores indicating a higher level of impairment. IADL and BADL were examined as both continuous and binary (no vs. impairment [score of 0 or 1] in 1+ activities) variables.

**Other Measures**
The socio-demographic, health and lifestyle characteristics of patients were assessed at baseline by study nurses [25]. Education was self-reported and recorded as number of completed full-time years since kindergarten. Anxiety was assessed with the State-Trait Anxiety Index [35] (state only), with higher scores indicating greater anxiety. Global cognitive performance was screened using the Mini-Mental State Exam (MMSE) [36]. Raw scores were used.

Baseline clinical data derived from the APPROACH database [28] included: admission diagnosis, ejection fraction, high risk coronary anatomy (i.e., double-vessel CAD with proximal left anterior descending artery involvement, any 3 vessel disease or left main disease), Canadian Cardiovascular Society (CCS) angina class, acute coronary syndrome, and disease history (cerebrovascular, congestive heart failure, peripheral vascular, diabetes mellitus, hypertension, hyperlipidemia, pulmonary, renal, malignancy, liver, gastrointestinal).
Missing Data, Value Assignment and Imputation

Two participants (with dementia at follow-up) unable to complete the GDS were assigned GDS scores based on CAMDEX Part H [27] caregiver questions about the participant’s mood. Missing OARS data was rare with approximately 0.36 % missing across all visits for each of the individual IADLs and about 0.19 % missing for each of the individual BADLs. In each case, a geriatrician (DH) reviewed all data collected for the participant and assigned a score based on previous and subsequent OARS responses, current performance test results, cognitive test results, and quality of life responses.

Statistical Analyses

Descriptive analyses were conducted to examine the distribution of patients’ socio-demographic and clinical characteristics overall and by depression status [25]. The 4-level categorical measure of depressive symptoms was examined with regard to mean change in continuous IADL and BADL scores between baseline and 6 months, 6 to 12 months, and 12 to 30 months using linear mixed models with a random intercept (function lmer in the lme4 package in R version 3.2.3) [37]. Restricted maximum likelihood (REML) was used to estimate the model parameters. To account for the impact of baseline covariates in changes over time, the models included interactions between time and age, sex, and baseline MMSE scores. We repeated these models also adjusting for a comorbidity measure (derived from selected diagnoses captured by the APPROACH database). As further adjustment for comorbidity did not alter our findings, we have presented the more parsimonious model estimates in this paper. The results were summarized in terms of generalized least squares (GLS) means with 95 % confidence intervals as well as mean differences with 95 % confidence intervals.

Secondary analyses used generalized estimating equations with an exchangeable correlation structure (function geeglm in the geepack package in R version 3.2.3) [37] to fit logistic regression models to evaluate changes in proportions of patients with any ADLs after accounting for baseline age, sex, and MMSE.

Results

The mean age of our sample was 71.3 (SD 5.9) years and 73.7 % were male. Over 1 year, 248 (71 %) participants exhibited no significant depressive symptoms, 32 (9 %) had baseline-only symptoms, 28 (8 %) were new onset cases (at 6 or 12 months), and 42 (12 %) showed persistent symptoms. Table 1 presents a comparison of baseline characteristics (and follow-up GDS scores) across these four categories. There were relatively few meaningful differences between the groups. Compared to subjects without symptoms at any assessment: (i) those with new onset symptoms were older, less educated, and more likely to be living alone, have marked/unstable angina, or an acute coronary syndrome; and, (ii) those with persistent symptoms were more likely to report poor self-rated health, have higher anxiety scores, and report a history of diabetes, marked/unstable angina or an acute coronary syndrome. Baseline mean MMSE scores were significantly lower among all 3 depressive symptom groups compared to those with no symptoms.

Among participants with new onset and persistent depressive symptoms, there was an increase in the proportion with any IADL impairment from baseline to 30 months. There was little change among those with no depressive symptoms and a decrease in proportion with any IADL impairment among patients with baseline only symptoms (Table 2, for adjusted estimates see Additional file 1: Fig. S1). There was a higher proportion with any BADL impairment at 30 months evident among subjects with new onset and persistent symptoms (Table 2, for adjusted estimates see Additional file 1: Fig. S2).

In models adjusted for age, sex and baseline MMSE score, subjects with persistent depressive symptoms showed a significant decrease in mean IADL and BADL scores from baseline to 6 months (−1.32 [95% CI −1.78 to −0.86] and −0.63 [−0.97 to −0.30], respectively) and from 12 to 30 months (−0.79 [−1.27 to −0.31] and −1.00 [−1.35 to −0.65], respectively) post-procedure (Tables 3 and 4; Figs. 2 and 3). Those with new onset depressive symptoms showed a significant decrease in mean IADL and BADL scores from baseline to 6 months (−0.80 [−1.37 to −0.24] and −0.84 [−1.25 to −0.43], respectively) and in mean IADL score from 6 to 12 months (−0.99 [−1.56 to −0.42]) follow-up. Participants with baseline only depressive symptoms showed a significant improvement in mean IADL score from baseline to 6 months (0.62 [0.09 to 1.15]) and relative stability in mean IADL and BADL scores across subsequent follow-up assessments. Subjects exhibiting no depressive symptoms during the 1 year post-procedure showed no significant change in mean IADL or BADL scores from baseline to 6 months or from 6 to 12 months; however they exhibited a significant but small decrease in mean IADL and BADL scores from 12 to 30 months post-procedure (−0.24 [−0.44 to −0.05] and −0.16 [−0.30 to −0.02], respectively).

Discussion

This study is one of but a few to explore the association between changes in depressive symptoms over time and long-term functional status among older CAD patients undergoing non-emergent catheterization. Patients with persistent symptoms experienced a significant decrease in mean IADL and BADL scores over the 30-month follow-up period post-procedure. A significant (but
Table 1 Baseline (and follow-up GDS) Characteristics of 3C Subjects by Depressive Symptom Change over 1 Year

| Depressive symptom category | None $n = 248$ | Baseline only $n = 32$ | New onset $n = 28$ | Persistent $n = 42$ | $P$-value* |
|-----------------------------|----------------|----------------------|-------------------|-------------------|------------|
| Sociodemographic and Lifestyle Factors | | | | | |
| Age: mean (SD) | 70.1 (5.8) | 71.0 (6.1) | 74.3 (6.5) | 71.7 (5.3) | 0.03 |
| Age 75+: n (%) | 57 (23.0) | 7 (21.9) | 9 (32.1) | 12 (28.6) | 0.11 |
| Male: n (%) | 186 (75.0) | 23 (71.9) | 18 (64.3) | 31 (73.8) | 0.67 |
| Education: mean (SD), y | 13.2 (3.8) | 11.5 (2.7) | 11.4 (4.3) | 12.2 (4.2) | 0.01 |
| Lives alone: n (%) | 31 (12.5) | 8 (25.0) | 9 (32.1) | 7 (16.7) | 0.02 |
| Current or past smoker: n (%) | 176 (71.0) | 23 (71.9) | 20 (71.4) | 30 (71.4) | >0.99 |
| Heavy drinker: n (%) | 48 (19.4) | 8 (25.0) | 4 (14.3) | 8 (19.0) | 0.77 |
| Treatment Group, n (%) | | | | | |
| CABG | 80 (32.3) | 13 (40.6) | 10 (35.7) | 18 (42.9) | 0.66 |
| PCI | 107 (43.1) | 13 (40.6) | 9 (32.1) | 14 (33.3) | |
| Medical Therapy | 61 (24.6) | 6 (18.8) | 9 (32.1) | 10 (23.8) | |
| Clinical Characteristics\(^a\) n (%) | | | | | |
| Admitted with stable angina (vs MI, unstable angina and other) | 168 (68.3) | 19 (61.3) | 16 (57.1) | 24 (57.1) | 0.37 |
| Ejection Fraction <50 % | 53 (21.5) | 9 (29.0) | 6 (21.4) | 9 (21.4) | 0.82 |
| High risk coronary anatomy\(^b\) | 105 (42.7) | 19 (61.3) | 16 (59.3) | 20 (48.8) | 0.17 |
| CCS angina class > II | 104 (42.3) | 19 (61.3) | 18 (64.3) | 26 (61.9) | 0.01 |
| Acute coronary syndrome | 53 (21.5) | 9 (29.0) | 11 (39.3) | 16 (38.1) | 0.04 |
| Medical History\(^a\) n (%) | | | | | |
| Cerebrovascular disease | 20 (8.1) | 4 (12.9) | 2 (7.1) | 8 (19.0) | 0.14 |
| Congestive heart failure | 22 (8.9) | 3 (9.7) | 5 (17.9) | 3 (7.1) | 0.45 |
| Peripheral vascular disease\(^c\) | 21 (8.6) | 2 (6.3) | 1 (3.6) | 7 (16.7) | 0.57 |
| Diabetes Mellitus (Type I or II) | 52 (21.1) | 11 (35.5) | 4 (14.3) | 15 (35.7) | 0.05 |
| Hypertension | 185 (75.2) | 27 (87.1) | 23 (82.1) | 33 (78.6) | 0.44 |
| Hyperlipidemia | 207 (84.1) | 24 (77.4) | 25 (89.3) | 34 (81.0) | 0.62 |
| Pulmonary disease | 48 (19.5) | 7 (22.6) | 8 (28.6) | 13 (31.0) | 0.31 |
| Renal disease | 5 (2.0) | 2 (6.3) | 1 (3.6) | 2 (4.8) | 0.45 |
| Malignancy | 12 (4.9) | 1 (3.2) | 2 (7.1) | 3 (7.1) | 0.84 |
| Severe/debilitating liver disease | 1 (0.4) | 1 (3.2) | 0 (0) | 0 (0) | 0.23 |
| Severe/debilitating gastrointestinal disease | 14 (5.7) | 3 (9.7) | 2 (7.1) | 7 (16.7) | 0.09 |
| Additional Clinical Information | | | | | |
| Baseline mean MMSE score (SD) | 28.5 (1.3) | 27.8 (2.0) | 27.6 (2.3) | 27.2 (2.6) | <0.001 |
| Previous stroke and/or TIA: n(%) | 27 (10.9) | 4 (12.5) | 5 (17.9) | 7 (16.7) | 0.57 |
| Self rated health-fair/poor: n(%)\(^d\) | 34 (13.8) | 16 (50.0) | 7 (25.0) | 23 (54.8) | <0.001 |
| Anxiety level (STAI score): mean (SD)\(^e\) | 32.7 (9.7) | 35.1 (9.2) | 35.2 (10.2) | 43.1 (10.2) | <0.001 |
| Baseline and Follow-up GDS Score | | | | | |
| Baseline GDS scores, mean (SD) | 1.76 (1.28) | 6.22 (1.64) | 2.39 (1.37) | 7.60 (2.67) | <0.001 |
smaller) decrease in mean IADL and BADL scores during selected assessment times over follow-up was also evident among patients with new onset depressive symptoms. In contrast, there was relative stability in IADL and BADL functioning among patients with no depressive symptoms or depressive symptoms at baseline only. Among the latter group, there was a small but significant improvement in mean IADL scores between baseline and 6 months post-procedure.

The overall magnitude of change observed in our IADL and BADL measures during the 30 months appears to approximate a clinically meaningful difference in functional status [18, 38, 39]. In their recent study of depressive symptoms among older adults with stable coronary heart disease, Sin and colleagues [18] argued for the clinical relevance of a 1-point decrease in comparable IADL and BADL measures on the basis that a change of this magnitude would capture those needing assistance with an additional activity (or shifting to complete dependence from partial assistance for an activity).

Our findings are consistent with the hypothesis that persistent or more severe depressive symptoms are associated with worse outcomes in this patient population [11, 19–21]. Although there is extensive literature linking depression to disability among older community-based adults [24] and medical patients [40], a unique contribution of our work is the focus on the dynamic nature of depressive symptoms in a CAD population undergoing coronary interventions and subsequent risk of long-term functional outcomes. An earlier publication based on this cohort showed that participants with persistent depressive symptoms (relative to those with no or baseline-only symptoms) exhibited significantly greater decline at 30 months in multiple cognitive domains, including attention/executive functioning [25]. Executive dysfunction would be expected to place patients at heightened risk for greater functional disability [24, 41, 42]. In the current analyses, we show that persistent symptoms also represent an independent risk factor for long-term functional disability.

### Table 1 Baseline (and follow-up GDS) Characteristics of 3C Subjects by Depressive Symptom Change over 1 Year (Continued)

| Depressive symptom category | 6 Month GDS scores, mean (SD) | 12 Month GDS scores, mean (SD) | 30 month GDS scores, mean (SD) |
|----------------------------|-----------------------------|-------------------------------|-------------------------------|
| None                       | 1.12 (1.18)                 | 1.18 (1.22)                   | 1.20 (1.46)                   |
| Baseline only              | 2.35 (1.33)                 | 1.78 (1.24)                   | 3.11 (2.25)                   |
| New onset                  | 5.61 (2.96)                 | 4.26 (2.86)                   | 3.41 (2.89)                   |
| Persistent                 | 7.19 (3.05)                 | 6.90 (3.26)                   | 7.70 (3.70)                   |

### Table 2 Percentage (95 % CI) of 3C Subjects with any IADL or BADL impairment at each assessment by Depressive Symptom Change over 1 Year

| Depressive symptom category | None Baseline only New onset Persistent |
|----------------------------|----------------------------------------|
| IADL impairment            |                                        |
| Baseline<sup>a</sup>       | 16.9 (12.8–22.1)                       |
| 6 Months<sup>b</sup>       | 21.0 (16.3–26.5)                       |
| 12 Months<sup>c</sup>      | 16.2 (12.1–21.4)                       |
| 30 months<sup>d</sup>      | 20.4 (15.6–26.1)                       |
| BDL impairment             |                                        |
| Baseline<sup>a</sup>       | 5.2 (3.1–8.8)                          |
| 6 Months<sup>b</sup>       | 8.2 (5.4–12.4)                         |
| 12 Months<sup>c</sup>      | 9.2 (6.1–13.5)                         |
| 30 Months<sup>d</sup>      | 10.6 (7.2–15.3)                        |

**Abbreviations:** 3C, calgary cardiac and cognition study; IADL, instrumental activities of daily living; BADL, basic activities of daily living

<sup>a</sup>Sample sizes are n = 248, n = 32, n = 28, n = 42 for none, baseline only, new onset and persistent groups, respectively

<sup>b</sup>Sample sizes are n = 243, n = 31, n = 28, n = 42 for none, baseline only, new onset and persistent groups, respectively

<sup>c</sup>Sample sizes are n = 240, n = 32, n = 27, n = 42 for none, baseline only, new onset and persistent groups, respectively

<sup>d</sup>Sample sizes are n = 226, n = 28, n = 27, n = 37 for none, baseline only, new onset and persistent groups, respectively
Several implications can be drawn from our work. First, depressive symptoms are not static among older adults with CAD undergoing coronary interventions. Some with clinically meaningful symptoms at baseline improve, while others have persistent problems that are associated with worse functional outcomes. The small but significant improvement in mean IADL scores observed between baseline and 6 months post-procedure among patients with depressive symptoms at baseline only illustrates this point. This sub-group may have experienced transient depressive symptoms in response to their health status pre-procedure or from anxiety about their diagnosis and impending procedure. The improvement in their disease symptoms and/or anxiety level post-procedure could explain both the absence of continued depressive symptoms and their increased likelihood for better functional status at 6 months. Our findings provide a rationale for assessing depressive symptoms at multiple time points (e.g., before and 6 or 12 months post-interventions). Information regarding new onset or persistent depressive symptoms could be used to delineate high-risk groups in need of targeted interventions to prevent or slow functional decline. The recognition of persistent symptoms may warrant greater secondary prevention efforts. Patients with persistent depressive symptoms may be at an increased risk for non-adherence [43] and consequently may require heightened surveillance. The significant improvement in IADL scores observed for patients with depressive symptoms at baseline only, suggests the potential for clinical interventions to alter functional trajectories.

Several possible mechanisms may explain why depressive symptoms are associated with worse functional status. Their presence could lead to functional limitations. Experienced depression may decrease motivation for, and reward from, physical and/or social activities important for the maintenance of functional independence. This is consistent with the finding that depressed patients are more difficult to engage in physical therapy, often crucial for recovery of function [44]. Depressive symptoms can amplify symptoms of medical illnesses [45], or affect adherence to medication regimens [43], worsening the course of various chronic conditions. Further, depressive symptoms might affect functioning through neuroendocrine and inflammatory mechanisms [46]. It is possible that depression may negatively influence a patient’s perceptions of what they are able to do [47], limiting their ability to participate in rehabilitation.

| Depression symptom category | Mean change from previous measure | P-value |
|-----------------------------|-----------------------------------|---------|
|                            | Estimate 95 % CI | Estimate 95 % CI |              |
| Baseline                   |                     |                     |              |
| None                       | 13.65 [13.44–13.86] | N/A | N/A | N/A |
| Baseline only              | 12.80 [12.22–13.39] | N/A | N/A | N/A |
| New onset                  | 13.58 [12.94–14.21] | N/A | N/A | N/A |
| Persistent                 | 13.03 [12.51–13.54] | N/A | N/A | N/A |
| 6 months                   |                     |                     |              |
| None                       | 13.53 [13.32–13.74] | −0.12 [−0.31–0.07] | 0.2118 |
| Baseline only              | 13.43 [12.84–14.01] | 0.62 [0.09–1.15] | 0.0208 |
| New onset                  | 12.77 [12.14–13.41] | −0.80 [−1.37–−0.24] | 0.0055 |
| Persistent                 | 11.71 [11.20–12.22] | −1.32 [−1.78–−0.86] | 0.0000 |
| 12 months                  |                     |                     |              |
| None                       | 13.62 [13.41–13.83] | 0.09 [−0.10–0.28] | 0.3652 |
| Baseline only              | 13.32 [12.74–13.90] | −0.11 [−0.63–−0.042] | 0.6904 |
| New onset                  | 11.79 [11.15–12.42] | −0.99 [−1.56–−0.42] | 0.0007 |
| Persistent                 | 11.85 [11.34–12.36] | 0.14 [−0.31–0.60] | 0.5360 |
| 30 months                  |                     |                     |              |
| None                       | 13.37 [13.16–13.59] | −0.24 [−0.44–−0.05] | 0.0146 |
| Baseline only              | 13.06 [12.45–13.66] | −0.26 [−0.80–0.28] | 0.3459 |
| New onset                  | 11.98 [11.34–12.61] | 0.19 [−0.38–0.76] | 0.5146 |
| Persistent                 | 11.06 [10.53–11.59] | −0.79 [−1.27–−0.31] | 0.0013 |

*model adjusted for age, sex and baseline MMSE.
Table 4 Generalized Least Squares Mean (95% Confidence Interval) Change in BADL<sup>a</sup> Over Time, by Depressive Symptom Change over 1 Year

| Depression symptom category | Mean Change from previous measure | P-value |
|-----------------------------|----------------------------------|---------|
|                             | Estimate | 95% CI | Estimate | 95% CI |         |
| Baseline                    |          |        |          |        |         |
| None                        | 13.92    | [13.78–14.06] | N/A | N/A | N/A |
| Baseline only               | 13.85    | [13.45–14.25] | N/A | N/A | N/A |
| New onset                   | 13.94    | [13.51–14.37] | N/A | N/A | N/A |
| Persistent                  | 13.46    | [13.11–13.81] | N/A | N/A | N/A |
| 6 months                    |          |        |          |        |         |
| None                        | 13.86    | [13.72–14.00] | −0.06 | [−0.20–0.08] | 0.4074 |
| Baseline only               | 13.79    | [13.39–14.19] | −0.06 | [−0.44–0.32] | 0.7538 |
| New onset                   | 13.10    | [12.67–13.53] | −0.84 | [−1.25–−0.43] | 0.0001 |
| Persistent                  | 12.83    | [12.48–13.17] | −0.63 | [−0.97–−0.30] | 0.0002 |
| 12 months                   |          |        |          |        |         |
| None                        | 13.81    | [13.67–13.96] | −0.05 | [−0.19–0.009] | 0.4870 |
| Baseline only               | 13.63    | [13.23–14.02] | −0.16 | [−0.54–0.22] | 0.4068 |
| New onset                   | 13.09    | [12.66–13.53] | −0.01 | [−0.42–0.41] | 0.9781 |
| Persistent                  | 12.92    | [12.58–13.27] | 0.09 | [−0.24–0.43] | 0.5738 |
| 30 months                   |          |        |          |        |         |
| None                        | 13.65    | [13.50–13.80] | −0.16 | [−0.30–−0.02] | 0.0268 |
| Baseline only               | 13.42    | [13.01–13.83] | −0.21 | [−0.60–0.18] | 0.2942 |
| New onset                   | 13.20    | [12.77–13.63] | 0.10 | [−0.31–0.52] | 0.6213 |
| Persistent                  | 11.92    | [11.55–12.28] | −1.00 | [−1.35–−0.65] | 0.0000 |

<sup>a</sup>model adjusted for age, sex and baseline MMSE score
programs. Conversely, impaired function might also lead to depressive symptoms because of the perceived loss of independence and mastery. We suspect the relationship between the two is bi-directional. Finally, both depressive symptoms and functional impairments might be secondary to factors such as small vessel cerebrovascular disease [48], worse control of the patients CAD [49, 50], or the presence (and impact) of other co-morbidities [51].

Strengths of our study include the longitudinal design and minimal lost to follow-up despite a long duration (30-month period), availability of detailed and repeat measures of patients’ clinical, cognitive and functional status, and inclusion of all three treatment options (CABG, PCI and MT) following catheterization in the 3C cohort. Our interpretations are limited by the observational nature of the study and some uncertainty about the clinical significance of the differences seen in IADL and BADL scores. The relatively small number of cases for a number of the categories limited our ability to include numerous covariates in our adjusted analyses. We were unable to explore sex and/or ethnic differences in our analyses because most patients were male and 95% were of European or unknown ethnicity. Due to the absence of information, we were also not able to explore the influence of a previous history of depressive symptoms, use of selected therapies (e.g., antidepressants, psychotherapy, cardiac rehabilitation) or the availability of social support on the observed associations between the evolution of depressive symptoms and functional decline. At the same time, it is noteworthy that there were few meaningful differences in the sociodemographic or clinical characteristics between patients with baseline only compared with persistent depressive symptoms, despite clear differences in their functional outcomes. As well, adjustment for variation in comorbidity (in addition to age, sex and MMSE scores) did not alter our findings. We believe the parsimonious approach we took to modeling was appropriate in this study as further adjustment for other covariates that were not observed to vary by depressive symptom category or that might be considered possible mediators of the association between depressive symptom change and functional decline may have posed a risk of unnecessary adjustment (leading to a loss of precision in estimates) or overadjustment bias (leading to a masking of relevant exposure—outcome associations), respectively [52]. Finally, our findings may have limited generalizability to other patient populations including CAD patient populations not undergoing invasive procedures, as all patients underwent coronary catheterization.

Conclusions
In our sample of older CAD patients undergoing coronary interventions, significant decreases in mean functional scores over the 30 month follow-up were observed for those with persistent (but not baseline only) depressive symptoms. This suggests a one-time assessment of depressive symptoms may be inadequate for determining which patients are at high-risk for adverse functional outcomes. Although there is little available research regarding the impact of depression treatment on functional outcomes, our findings illustrate the need for longer-term monitoring and further large-scale evaluation of management strategies (pharmaceutical and non-pharmaceutical) for depression in CAD patients. A number of recent studies have shown that a collaborative care model, where both depression and cardiovascular disease are simultaneously managed in the primary care setting with the aid of a consulting psychiatrist, may result in a significant (albeit modest) reduction in depressive symptoms [53, 54]. Whether or not such multifaceted interventions have a meaningful impact on the quality of life and functional outcomes of older CAD patients remains to be determined.

Main Bullet Points
- Patients with persistent depressive symptoms were at greatest risk for worse functional status (assessed as decline in instrumental [IADL] and basic [BADL] activities of daily living) 30 months following coronary interventions.
- Patients with no depressive symptoms or depressive symptoms at baseline only showed relative stability in their IADL and BADL functioning over time.
- Repeated screening for depression in older patients with coronary artery disease offers prognostic value and may facilitate the implementation of targeted strategies to optimize long-term functional outcomes.

Additional file

Additional file 1: Figure S1. (Percentage [95% confidence interval] of 3C Subjects with any IADL impairment at each assessment by depressive symptom change over 1 year; Figure S2. (Percentage [95% confidence interval] of 3C Subjects with any BADL impairment at each assessment by depressive symptom change over 1 year). (DOCX 297 kb)

Abbreviations
3C, calgary cardiac and cognition study; APPROACH, Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease; BAPL, basic activities of daily living; CABG, coronary artery bypass graft; CAD, coronary artery disease; CAMDEX-R, Cambridge Mental Disorders of the Elderly Examination-Revised; CCS, Canadian Cardiovascular Society; GDS, geriatric depression scale; GLS, generalized least squares; IADL, instrumental activities of daily living; MMSE, mini-mental state exam; MT, medical therapy; OARS, Older Americans Resources and Services; PCI, percutaneous coronary intervention; REML, restricted maximum likelihood; SD, standard deviation; STAI, State-Trait Anxiety Index
Acknowledgements
The authors wish to thank the 3C study coordinators and research nurses for their assistance with project management and data collection. Thanks are also given to the 3C study investigators for their clinical assistance. We are especially grateful to all the 3C participants and their families for their significant contributions to the study.

Funding
Funding for this study was received from the Canadian Institutes of Health Research (CIHR) Institute of Aging (IAO-63151); the M.S.I. Foundation (#810); and, the Brenda Strafford Foundation Chair for Geriatric Medicine. Dr. Hogan holds and receives funding from the Brenda Strafford Foundation Chair in Geriatric Medicine, University of Calgary. Dr. Anderson holds the Merck Frost Chair in Cardiovascular Research. Dr. Demchuk holds the Heart and Stroke Foundation Chair in Stroke Research. The funding organizations played no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review or approval of the manuscript.

Availability of data and materials
The datasets generated during and/or analysed during the current study are not publicly available due to ethical and privacy guidelines. Summarized and/or aggregated data (that comply with existing ethical and privacy guidelines) are available from the corresponding author on reasonable request.

Authors’ contributions
MEW wrote the first draft and revised the manuscript. EAF and PF conceived the analytical approach, analyzed data, and revised the manuscript. CJM conceived and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Ethics approval was obtained from the Conjoint Health Research Ethics Board, University of Calgary and informed consent was obtained from all participants.

Author details
1Department of Medicine, Division of Respirology, University Health Network, Toronto, Canada. 2Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Canada. 3Institute of Social Research, University of Michigan, Ann Arbor, USA. 4Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada. 5Research, Innovation and Analytics, Alberta Health Services, Foothills Medical Centre, Calgary, Canada. 6Department of Medicine (Division of Geriatric Medicine), Cumming School of Medicine, University of Calgary, Calgary, Canada. 7Department of Psychiatry and Mathison Centre for Mental Health Research and Education, Cumming School of Medicine, University of Calgary, Calgary, Canada. 8Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada. 9Department of Cardiac Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada. 10Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Canada. 11Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Canada. 12Schools of Pharmacy and Public Health and Health Systems, University of Waterloo, 200 University Avenue West, Waterloo N2L 3G1, ON, Canada. 13Institute for Clinical Evaluative Sciences (ICES), Toronto, Canada.

Received: 3 February 2016 Accepted: 28 July 2016
Published online: 04 August 2016

References
1. Ng TP, Niti M, Tan WC, Cao Z, Ong KC, Eng P. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med. 2007;167:60–7.
2. Parashar S, Rumsfeld JS, Speratus JA, Reid KJ, Wenger NK, Krumholz HM, et al. Time course of depression and outcome of myocardial infarction. Arch Intern Med. 2006;166:2035–43.
3. Covinsky KE, Fortinsky RH, Palmer RM, Kresevic DM, Landefeld CS. Relation between symptoms of depression and health status outcomes in acutely ill hospitalized older persons. Ann Intern Med. 1997;126:417–25.
4. Mccusker J, Lattimer E, Cole M, Ciampi A, Seward RF. Major depression among medically ill elders contributes to sustained poor mental health in their informal caregivers. Age Ageing. 2007;36:400–6.
5. Jiang W, Alexander J, Christopher E, Kuchibhatla M, Gaulden LH, Cuffe MS, et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med. 2001;161:1849–56.
6. Jiang W, Kuchibhatla M, Clary GL, Cuffe MS, Christopher EJ, Alexander JD, et al. Relationship between depressive symptoms and long-term mortality in patients with heart failure. Am Heart J. 2007;154:102–8.
7. Connorney J, Sloan RP, Shapiro PA, Bagiella E, Seckman C. Depression is associated with increased mortality 10 years after coronary artery bypass surgery. Psychiatr Med. 2010;72:874–81.
8. Camey RM, Freedland KE. Depression in patients with coronary heart disease. Am J Med. 2008;119:520–7.
9. Timberlake N, Klinger L, Smith P, Venn G, Treasure T, Harrison M, et al. Incidence and patterns of depression following coronary artery bypass graft surgery. J Psychiatr Res. 1997;31:197–207.
10. Meeks TW, Vahia IV, Lavretsky H, Kulkarni G,Jeste DV. A tune in “a minor” can “b major”: A review of epidemiology, illness course, and public health implications of subthreshold depression in older adults. J Affect Disord. 2011;129:126–42.
11. Blumenthal JA, Leitz HS, Babakay MA, White W, Smith PK, Mark DB, et al. Depression as a risk factor for mortality after coronary artery bypass surgery. Lancet. 2003;362:604–9.
12. van Melle JP, de jonge P, Spipelman TA, Tijssen JG, Ormel J, van Veldhuisen DJ, et al. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med. 2004;66:814–22.
13. Speratus JA, Mondonell M, Woodman CL, Fihn SD. Association between depression and worse disease-specific functional status in outpatients with coronary artery disease. Am Heart J. 2005;140:105–10.
14. Sullivan MD, Lacroix AZ, Spertus JA, Hecht J. Five-year prospective study of the effects of anxiety and depression in patients with coronary artery disease. Am J Cardiol. 2000;86:1135–8.
15. de Jonge P, Spipelman TA, van den Brink RH, Ormel J. Depression after myocardial infarction is a risk factor for declining health related quality of life and increased disability and cardiac complaints at 12 months. Heart. 2006;92:33–9.
16. Hybels CF, Pieper CF, Blazer DG, Steffens DC. Heterogeneity in the three-year course of major depression among older adults. Int J Geriatr Psychiatry. 2016;31:775–82.
17. Graham MM, Ghali WA, Faris PD, Gubbaith PD, Norris CM, Knudston ML. Alberta Provincial Project for Outcomes Assessment in Coronary Heart Disease (APPROACH) Investigators. Survival after coronary revascularization in the elderly. Circulation. 2002;105:2378–94.
18. Sin NL, Yaffe K, Woolley MA. Depressive symptoms, cardiovascular disease severity, and functional status in older adults with coronary heart disease: the heart and soul study. J Am Geriatr Soc. 2015;63:88–95.
19. Camey RM, Freedland KE, Steinmeyer BC, Blumenthal JA, de Jonge P, Davidson KW, et al. History of depression and survival after acute myocardial infarction. Psychosom Med. 2009;71:253–9.
20. de Jonge P, Honig A, van Melle JP, Schene AH, van den Brink RH, Ormel J, et al. Nonresponse to treatment for depression following myocardial infarction: Association with subsequent cardiac events. Am J Psychiatry. 2007;164:1371–8.
21. Lespérance F, Fraure-Smith N, Talajic M, Bourassa MG, Hachinski VC. Depression following myocardial infarction and mortality in relation to initial severity and one-year changes in depression. J Cardiopulm Rehabil Prev. 2002;21:105–9.
22. Kohler S, van Bostel VP, van Ors J, Thomas AJ, O'Brien JT, Jolles J, et al. Depressive symptoms and cognitive decline in community-dwelling older adults. J Am Geriatr Soc. 2010;58:873–9.
23. Singh-Manoux A, Akbaraly TN, Marmot M, Felch M, Anker J, Sabia S, et al. Persistent depressive symptoms and cognitive function in late midlife: the Whitehall II study. J Clin Psychiatry. 2010;71:1379–85.
et al. BMC Psychiatry (2016) 16:277

24. Lenze EJ, Schulz R, Martire LM, Zdaniuk B, Glass T, Kop WJ, et al. The course of functional decline in older people with persistently elevated depressive symptoms: longitudinal findings from the Cardiovascular Health Study. J Am Geriatr Soc. 2005;53:569–73.

25. Freheits EA, Hogan DB, Ekdaziz M, Patten SB, Demchuk AM, Faris P, et al. A dynamic view of depressive symptoms and neurocognitive change among patients with coronary artery disease. Arch Gen Psychiatry. 2012;69:44–55.

26. Freheits EA, Hogan DB, Patten SB, Wunsch C, Anderson T, Ghali WA, et al. Frailty trajectories after treatment for coronary artery disease in older persons. Circ Cardiovasc Qual Outcomes. 2016;9:230–8.

27. Roth M, Huppert FA, Mountjoy CQ, Tym E. The Cambridge Examination for Mental Disorders of the Elderly—Revised (CAMDEX-R Schedule). Cambridge: Cambridge University Press; 1998.

28. Ghali WA, Knudsson ML. Overview of the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease. On behalf of the APPROACH investigators. Can J Cardiol. 2000;16:1225–30.

29. Yesavage JA, Sheirli JK. Geriatric Depression Scale (GDS): Recent Evidence and Development of a Shorter Version. Clin Gerontol. 1986;5:165–73.

30. Almeida OP, Almeida SA. Short versions of the geriatric depression scale: a study of their validity for the diagnosis of a major depressive episode according to ICD-10 and DSM-IV. Int J Geriatr Psychiatr. 1999;14:588–65.

31. McDowell I, Newell C. Measuring Health: A Guide to Rating Scales and Questionnaires [2nd Ed]. New York: Oxford University Press; 1996. p. 259–63.

32. Friedman B, Heisel MJ, Delvan RL. Psychometric properties of the 15-item Geriatric Depression Scale in functionally impaired, cognitively intact, community-dwelling elderly primary care patients. J Am Geriatr Soc. 2005;53:1570–6.

33. Lyneis JM, Noel TK, Cox C, King DA, Conwell Y, Caine ED. Screening for depression in elderly primary care patients: A comparison of the Center for Epidemiologic Studies—Depression Scale and the Geriatric Depression Scale. Arch Intern Med. 1997;157:449–54.

34. Fillenbaum GG, Smyer MA. The development, validity, and reliability of the OARS multidimensional functional assessment questionnaire. J Gerontol. 1981;36:428–34.

35. Spielberger C, Gorskuch R, Lushene R. State-Trait Anxiety Inventory (STAI) Manual. Palo Alto: Consulting Psychologists Press; 1970.

36. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.

37. R Development Core Team (2011). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org/. Accessed 2 Aug 2016.

38. Abdulaziz K, Brehaut J, Taljaard M, Émond M, Sirois MJ, Lee JS, et al. National survey of emergency physicians to define functional decline in elderly patients with minor trauma. CJEM. 2015;17:639–47.

39. Provencher V, Sirois MJ, Oueltet MC, Camden S, Neveux X, Allain-Boulé N, et al. Decline in activities of daily living after a visit to a Canadian emergency department for minor injuries in independent older adults: are frail older adults with cognitive impairment at greater risk? J Am Geriatr Soc. 2015;63:860–8.

40. Pierluissi E, Mehta KM, Kirby KA, Boscardin WI, Fortinsky RH, Palmer RW, et al. Depressive Symptoms after hospitalization in older adults: function and mortality outcomes. J Am Geriatr Soc. 2012;60:2254–62.

41. Hart RP, Bean MK. Executive function, intellectual decline and daily living skills. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2011;18:64–85.

42. Johnson JK, Lui L-Y, Yaffe K. Executive function, more than global cognition, predicts functional decline and mortality in elderly women. J Gerontol A Biol Sci Med Sci. 2007;62:1134–41.

43. Dimatteo MR, Lepper HS, Crophic TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160:2101–7.

44. Desai SV, Law TJ, Needham DM. Long-term complications of critical care. Crit Care Med. 2011;39:371–9.

45. Katon WJ, Lin E, Russo J, Unutzer J. Increased medical costs of a population-based sample of depressed elderly patients. Arch Gen Psychiatry. 2003;60:897–903.

46. Tsigos C, Chrousos GP. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosom Res. 2002;53:865–71.

47. Callahan CM, Kronenke K, Counsell SR, Hendrie HC, Perkins AJ, Katon W, et al. Treatment of depression improves physical functioning in older adults. J Am Geriatr Soc. 2005;53:367–73.

48. Pan A, Sun Q, Okereke OI, Rexrode KM, Hu FB. Depression and risk of stroke morbidity and mortality: A meta-analysis and systematic review. JAMA. 2011;306:1241–9.

49. May HT, Horne BD, Calhquist JF, Sheng X, Joy E, Catnella AP. Depression after coronary artery disease is associated with heart failure. J Am Coll Cardiol. 2009;53:1440–7.

50. Kendell F, Gelbrich G, Wirtz M, Lehmkuhl E, Knoll N, Hetzer R, et al. Predictive relationship between depression and physical functioning after coronary surgery. Arch Intern Med. 2010;170:1717–21.

51. Eggermont LHP, de Boer K, Muller M, Jaschke AC, Kamp O, Scherder EJAJ. Cardiac disease and cognitive impairment: a systematic review. Heart. 2012;98:1334–40.

52. Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology. 2009;20:488–95.

53. Coventry P, Lovell K, Dickens C, Bower P, Chew-Graham C, Mcelvenny D, et al. Integrated primary care for patients with mental and physical multimorbidity: cluster randomised controlled trial of collaborative care for patients with depression comorbid with diabetes or cardiovascular disease. BMJ. 2015;350: h638. doi:10.1136/bmj.h638.

54. Huffman JC, Mastromauro CA, Beach SR, Celano CM, DuBois CM, Healy BC, et al. Collaborative care for depression and anxiety disorders in patients with recent cardiac events: The Management of Sadness and Anxiety in Cardiology (MOSAC) randomized clinical trial. JAMA Intern Med. 2014;174:927–35.

Submit your manuscript at www.biomedcentral.com/submit